| Authors: |
Emdin CA; Center for Genomic Medicine, Massachusetts General Hospital, Boston (C.A.E., A.V.K.).; Cardiovascular Disease Initiative, Broad Institute of MIT and Harvard (C.A.E., M.W., A.V.K.)., Bhatnagar P; Eli Lilly and Co, Indianapolis, IN (P.B., S.G.P., H.-R.Q., J.S.R., G.R.)., Wang M; Cardiovascular Disease Initiative, Broad Institute of MIT and Harvard (C.A.E., M.W., A.V.K.)., Pillai SG; Eli Lilly and Co, Indianapolis, IN (P.B., S.G.P., H.-R.Q., J.S.R., G.R.)., Li L; BioStat Solutions, Inc, Frederick, MD (L.L.)., Qian HR; Eli Lilly and Co, Indianapolis, IN (P.B., S.G.P., H.-R.Q., J.S.R., G.R.)., Riesmeyer JS; Eli Lilly and Co, Indianapolis, IN (P.B., S.G.P., H.-R.Q., J.S.R., G.R.)., Lincoff AM; The Cleveland Clinic Coordinating Center for Clinical Research, Department of Cardiovascular Medicine, Cleveland Clinic, OH (A.M.L., S.E.N.)., Nicholls SJ; Monash Cardiovascular Research Centre, Monash University, Clayton VIC, Australia (S.J.N.)., Nissen SE; The Cleveland Clinic Coordinating Center for Clinical Research, Department of Cardiovascular Medicine, Cleveland Clinic, OH (A.M.L., S.E.N.)., Ruotolo G; Eli Lilly and Co, Indianapolis, IN (P.B., S.G.P., H.-R.Q., J.S.R., G.R.)., Kathiresan S; Verve Therapeutics, Cambridge, MA (S.K.)., Khera AV; Center for Genomic Medicine, Massachusetts General Hospital, Boston (C.A.E., A.V.K.).; Cardiovascular Disease Initiative, Broad Institute of MIT and Harvard (C.A.E., M.W., A.V.K.). |
